Med Ad Hall of Fame to induct Lerner, Girgenti and Rubin

Share this article:
A 1960s ad for Librium
A 1960s ad for Librium
The Medical Advertising Hall of Fame named former Roche chief Irwin Lerner and medical advertising men Steven Girgenti and Mel Rubin as its 2010 inductees.

Having started his career with Organon as a copywriter and worked as a sales promotion manager with Geigy Pharmaceuticals, Lerner joined Roche in 1962 as advertising product manager for Librium and was named director of advertising ahead of the launch of Valium. He went on to spend 32 years with the company – 12 of them as CEO – during which he developed successful campaigns positioning Librium for anxiety and Valium for psychic tension, introduced a private hospital TV network and forged the lucrative Roche/GSK co-promotion deals for Zantac and Ceftin.

Girgenti, most recently of Ogilvy Healthworld, got his start with Squibb, Carter Wallace and Endo DuPont, where he was instrumental in the development and launch of Percocet. He moved on to superagency William Douglas McAdams before co-founding Bologna International and then Girgenti, Hughes, Butler & McDowell, along the way creating a logarithm for Theo Dur that helped boost sales from $12 million to $100 million in under three years. He took Girgenti, Hughes, Butler & McDowell public in 1997.

Rubin, a copywriter, founded the Shaller Rubin Company in 1950, an agency with clients including Schering, Geigy, Ciba, Pfizer, Marion Merrel Dow and Norwich Eaton. He was an early advocate of DTC TV advertising and his shop Rubin, Reid, Noto and Ehrenthal was the launch agency for Marion Merrell Dow's Nicorette gum TV campaign, the first-ever branded TV campaign for a prescription drug.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...